MCL1 and leukemia: HHT and gilteritinib can upregulate Ubiquitin Conjugating Enzyme E2 L6 (UBE2L6) together, promoting the degradation of Mcl-1 through the ubiquitin-proteasome pathway, and bring an effective drug target for FLT3-ITD mutated leukemia (200).